145 related articles for article (PubMed ID: 33052561)
1. Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c
Magalhaes I; Fernebro J; Abd Own S; Glaessgen D; Corvigno S; Remberger M; Mattsson J; Dahlstrand H
Adv Ther; 2020 Dec; 37(12):5023-5031. PubMed ID: 33052561
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
3. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
[TBL] [Abstract][Full Text] [Related]
4. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer.
Nunes M; Pacheco F; Coelho R; Leitão D; Ricardo S; David L
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162954
[TBL] [Abstract][Full Text] [Related]
6. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
7. Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells.
Wang DH; Wu XH; Qian SM; Yao HR
Med Oncol; 2015 Apr; 32(4):116. PubMed ID: 25779534
[TBL] [Abstract][Full Text] [Related]
8. Interpatient variability in mesothelin expression necessitates its evaluation before gastric cancer immunotherapy.
Sotoudeh M; Mansouri V; Shakeri R; Sharififard B; Sajadi N; Naderi M
Immunotherapy; 2022 May; 14(7):531-538. PubMed ID: 35321580
[No Abstract] [Full Text] [Related]
9. Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.
Hanaoka T; Hasegawa K; Kato T; Sato S; Kurosaki A; Miyara A; Nagao S; Seki H; Yasuda M; Fujiwara K
Mol Diagn Ther; 2017 Apr; 21(2):187-198. PubMed ID: 28160193
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays.
Shiraishi T; Shinto E; Nearchou IP; Tsuda H; Kajiwara Y; Einama T; Caie PD; Kishi Y; Ueno H
Virchows Arch; 2020 Sep; 477(3):409-420. PubMed ID: 32107600
[TBL] [Abstract][Full Text] [Related]
11. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.
Chang MC; Chen CA; Chen PJ; Chiang YC; Chen YL; Mao TL; Lin HW; Lin Chiang WH; Cheng WF
Biochem J; 2012 Mar; 442(2):293-302. PubMed ID: 21999204
[TBL] [Abstract][Full Text] [Related]
13. High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
Corvigno S; Mezheyeuski A; De La Fuente LM; Westbom-Fremer S; Carlson JW; Fernebro J; Åvall-Lundqvist E; Kannisto P; Hedenfalk I; Malander S; Rolny C; Dahlstrand H; Östman A
Gynecol Oncol; 2020 Dec; 159(3):860-868. PubMed ID: 33032823
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
15. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
Kakimoto S; Miyamoto M; Einama T; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Takano M
Pathol Oncol Res; 2020 Oct; 26(4):2299-2306. PubMed ID: 32468249
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H
BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
[No Abstract] [Full Text] [Related]
18. High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study.
Takamizawa S; Yazaki S; Kojima Y; Yoshida H; Kitadai R; Nishikawa T; Shimoi T; Sudo K; Okuma HS; Tanioka M; Noguchi E; Uno M; Ishikawa M; Kato T; Fujiwara Y; Yonemori K
BMC Cancer; 2022 Nov; 22(1):1215. PubMed ID: 36434635
[TBL] [Abstract][Full Text] [Related]
19. Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.
Lamberts LE; de Groot DJ; Bense RD; de Vries EG; Fehrmann RS
Oncotarget; 2015 Sep; 6(29):28164-72. PubMed ID: 26172299
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]